Researchers have unveiled a new “Trojan horse” obesity drug that dramatically amplifies weight loss and blood sugar control in early tests, potentially redefining how metabolic diseases like type 2 diabetes are treated.
In a preclinical study published in Nature, a team led by metabolism expert Prof. Timo D. Müller at Helmholtz Munich designed a hybrid molecule that hijacks the body’s own cellular machinery. The compound uses the well-known GLP-1/GIP signalling pathway as an entry point—then, once inside, delivers a secondary metabolic compound directly where it is needed.
The result? In laboratory tests, mice treated with the new agent ate less food, shed significantly more weight, and achieved superior blood-glucose control compared to standard treatments.
Beyond Current GLP-1-Based Therapies
Modern incretin therapies (drugs that mimic natural satiety and blood-sugar signals) have already transformed obesity and diabetes care. But researchers have long sought to add complementary drugs that improve how cells respond to insulin, helping glucose move more efficiently from the bloodstream into tissues.
The obstacle is that many of these additional drugs affect the entire body, raising the risk of side effects.
“Our guiding question was: how can we enhance incretin activity without creating a second, systemically active source of side effects?” says Prof. Müller, Director of the Institute for Diabetes and Obesity (IDO) at Helmholtz Munich, Professor at LMU Munich, and researcher at the German Center for Diabetes Research (DZD).
‘Address Label With Cargo’ Design
To solve this, the team chemically fused a known incretin-based compound with lanifibranor, a pan-PPAR agonist. The incretin portion acts like an “address label,” binding to GLP-1 or GIP receptors on the cell surface. Once the hybrid molecule enters, the second component activates PPARs—molecular “switches” in the cell nucleus that control genes involved in fat and sugar metabolism.
This design concentrates the added metabolic punch inside GLP-1R/GIPR-expressing cells instead of flooding the whole body.
A True ‘Trojan Horse’ Strategy
Functionally, the molecule hits five targets at once: two receptors on the cell surface (GLP-1R and GIPR) and three PPAR switches within the cell. Prof. Müller compares it to the legendary Trojan horse—the incretin component opens the gate, and the hidden drug only acts after it’s inside.
“A major advantage is the amount,” says Müller. “Because the second component is not administered separately and systemically, but ‘travels along’ with the incretin part, it can be used at a dose that is orders of magnitude lower.”
That targeted delivery could boost effectiveness while curbing side effects linked to widespread drug exposure.
Stronger Weight Loss, Better Metabolism
In mice with diet-induced obesity, the hybrid drug outperformed existing therapies.
“The animals ate less and lost more weight than under a GLP-1/GIP co-agonist without cargo,” says Dr. Daniela Liskiewicz, group leader at IDO and co-first author alongside Dr. Aaron Novikoff. “In the head-to-head comparisons shown, the effect was in part even stronger than with a GLP-1-only drug.”
Beyond weight loss, treated mice showed improved blood-glucose levels and signs of better insulin function—meaning insulin worked more effectively to move glucose from blood into tissues, while the liver released less glucose into circulation.
Reassuringly, common gastrointestinal side effects mirrored those seen with current incretin drugs. Crucially, researchers detected no signs of fluid retention or anemia, known concerns with the added drug component alone.
From Bench to Bedside
Early data also hinted at possible benefits for heart and liver health, though the team stresses these are preclinical findings. The GIP receptor differs between mice and humans, so identical results are not guaranteed.
“We see a principle with strong effects in the animal model, now the task is to optimise the approach for humans and move it towards the clinic,” says Müller. He notes that advancing this work will require collaboration with industry partners.
For now, the Trojan horse strategy offers a bold new direction: using one drug as the delivery vehicle for another, achieving supercharged metabolic benefits with a lower risk of systemic side effects. If successful in human trials, it could become the next major leap in obesity and diabetes therapy.